Veliparib (ABT-888)

Veliparib (ABT-888) is an inhibitor of PARP and PARP1 and related targets used in studies of DNA Damage Response and Apoptosis and related signaling programs. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to checkpoint activation, DNA repair, and genome-stability control and caspase-associated cell-death signaling and survival decisions in apoptosis, autophagy, and cancer models.

By inhibiting PARP and PARP1 and related targets, Veliparib (ABT-888) can be used to examine checkpoint activation, DNA repair, and genome-stability control and caspase-associated cell-death signaling and survival decisions. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving PARP and PARP1 and related targets
• Pathway perturbation studies connected to DNA Damage Response and Apoptosis and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Enzyme-activity assays, substrate-conversion studies, and mechanism profiling

Overall, Veliparib (ABT-888) is appropriate when a defined chemical perturbant is needed to connect PARP and PARP1 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.